Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: A multi-institutional study

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 128-137

  Matsumoto, Tetsuya ^a   Hanaki, Hideaki ^b   Kimura, Toshimi ^c   Nemoto, Manabu ^d   Higashihara, Masaaki ^e   Yokota, Hiroyuki ^f   Oda, Shigeto ^g   Akiyama, Nobu ^h   Miyao, Naoki ⁱ   Yoshida, Minoru ^h   Yukioka, Tetsuo ^a   Soma, Kazui ^e   Ohyashiki, Kazuma ^a   Suzuki, Yukio ^b   Arai, Takao ^a   Ikegami, Keiichi ^j   Ichiwata, Toshio ^k   Otsuka, Yoshihito ^l   Kobayashi, Masahiro ^m   Totsuka, Kyoichi ⁿ   Sunakawa, Keisuke ^b   more..

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NIPPON KOKAN HOSPITAL   (Japan)

^j DOKKYO MEDICAL UNIVERSITY   (Japan)

^k TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^l KAMEDA MEDICAL CENTER   (Japan)

^m KITASATO UNIVERSITY HOSPITAL   (Japan)

ⁿ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Arbekacin; Dosage regimen; Peak concentration; Pneumonia; Sepsis

Indexed keywords

CREATININE; HABEKACIN;

ADULT; AGED; ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SERUM TROUGH CONCENTRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; SIDE EFFECT; THROMBOCYTE COUNT;

EID: 84874108462     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0519-z     Document Type: Article

References (18)

1. Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man. Jpn J Antibiot. 1994;47:676-92.
2. Niijima T. New antimicrobial agent series XL: arbekacin. Jpn J Antibiot. 1991;44:705-17.
3. ® Injection, version 7, 2011.
4. Tanikaze N, Komatsu M, Shimakawa K, Yamamoto I. Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection. Jpn J Chemother. 2004;52:469-73.
5. Aikawa N, Kohno S, Kaku M, Watanabe A, Yamaguchi K, Tanigawara Y. An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) - a clinical pharmacology study. Jpn J Chemother. 2008;56:299-312.
6. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(Suppl 1):35S-43S.
7. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977;21:362-9.
8. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997;41:1115-9.
9. Kobayashi M, Takesue Y, Tanigawara Y, Mikamo H, Kimura T, Hirata S, et al. Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Jpn J Chemother. 2010;58:119-24.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. Sato N, Miura Y, Mitomi N, Hayashi H, Suzuki H, Shibasaki S, et al. Population pharmacokinetic analysis of arbekacin sulfate in adult patients. Jpn J Ther Drug Monit. 2010;27:98-110.
12. Kimura T, Sunakawa K, Totsuka K, Matsumoto T, Hanaki H, Soma K, et al. Dose finding study on arbekacin sulfate for appropriate peak levels. Jpn J Chemother. 2011;59:597-604.
13. Ferreira FL, Bota DP, Bross A, Melot C, Vincent J-L. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-8.
14. The Japanese Respiratory Society. The committee for the JRS guidelines in management of respiratory infections: the JRS guidelines for the management of hospital-acquired pneumonia in adults. Kyorin-sha: Tokyo; 2008; p. 4.
15. Kawano H, Tanigawara Y. Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring. Jpn J Ther Drug Monit. 2010;27:55-71.
16. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis. 2012;31:1663-6.
17. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
18. Yamamoto Y, Iumikawa K, Hashiguchi K, Kakeya H, Yanagihara K, Kohno S, et al. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J Infect Chemother. 2012;18:241-6.